Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis
Precision Radiation Oncology · 2026-06 · 10 (2) · 155-164
DOI: 10.1002/pro6.70076 ↗At a glance
Journal article in Precision Radiation Oncology, published online on 2026-05-30. Written by Mingqiang Lin and 5 co-authors. Institution: Department of Radiation Oncology Clinical Oncology School of Fujian Medical University Fujian Cancer Hospital Fuzhou Fujian China. 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Fujian Province.
Abstract (original language)
Background
The optimal management of locally advanced resectable esophageal squamous cell carcinoma (ESCC), particularly for cT3‐4a disease, remains debated. This study aimed to compare the survival outcomes and toxicity profiles of neoadjuvant chemoradiotherapy (NCRT) and adjuvant chemoradiotherapy (ACRT) in this patient population.
Methods
We retrospectively analyzed 223 patients with resectable cT3‐4a ESCC who underwent radical surgery combined with NCRT or ACRT. Propensity score matching (PSM) was used to generate 59 balanced pairs for comparative analysis.
Results
After matching, the NCRT group demonstrated significantly improved overall survival (OS) compared with the ACRT group, with a median OS of 62 versus 46 months and 5‐year OS rates of 66.6% versus 47.5%, respectively ( p = 0.023). Despite the longer median progression‐free survival (PFS) observed in the NCRT group (53 vs . 42 months), the difference in the 5‐year PFS rate was not statistically significant (56.7% vs . 44.4%; p = 0.113). Furthermore, the two groups exhibited similar profiles of treatment‐related adverse events (all p > 0.05). Multivariable analysis identified treatment strategy, body mass index (BMI), and clinical nodal (cN) status as independent predictors of OS (all p < 0.01). A novel prognostic score (PS) integrating BMI and cN status effectively stratified patients into distinct risk categories, with higher scores predicting poorer prognosis but not in the neoadjuvant subgroup.
Conclusions
For patients with resectable cT3‐4a ESCC, NCRT provides superior OS compared to ACRT, with similar PFS and toxicity. These findings support the prioritization of NCRT for this disease stage; however, larger randomized trials are warranted to optimize patient selection.
Subjects
Author keywords
Authors and institutions
- Department of Radiation Oncology Clinical Oncology School of Fujian Medical University Fujian Cancer Hospital Fuzhou Fujian China.
- Department of Radiation Oncology Putian University Affiliated Hospital Putian Fujian China.
- Department of Radiation Oncology Fujian Medical University Union Hospital Fuzhou Fujian China.
ORCID profiles: Jiancheng Li
Funding
- Natural Science Foundation of Fujian Province
Cite
APA
Lin, M., Yu, Y., Hu, Y., Zheng, R., Li, J., & Yao, Q. (2026). Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis. Precision Radiation Oncology, 10(2), 155-164. https://doi.org/10.1002/pro6.70076
Vancouver
Lin M, Yu Y, Hu Y, Zheng R, Li J, Yao Q. Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis. Precision Radiation Oncology. 2026;10(2):155-164. doi:10.1002/pro6.70076
BibTeX
@article{Lin2026,
author = {Lin, Mingqiang and Yu, Yilin and Hu, Yibing and Zheng, Rong and Li, Jiancheng and Yao, Qiwei},
title = {Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis},
journal = {Precision Radiation Oncology},
year = {2026},
volume = {10},
number = {2},
pages = {155--164},
doi = {10.1002/pro6.70076}
}
EUVIMED